Nektar Therapeutics (NKTR) Sees Early Weakness
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Nektar Therapeutics (NASDAQ: NKTR) is under heavy pressure this morning. Shares are down 8.6% on volume that is running 49x normal.
This morning, Bristol-Myers Squibb Company (NYSE: BMY) and Nektar Therapeutics announced a new clinical collaboration to evaluate Bristol-Myers Squibb’s Opdivo (nivolumab) with Nektar’s investigational medicine, NKTR-214, as a potential combination treatment regimen in five tumor types and seven potential indications. Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression. NKTR-214 is an investigational immuno-stimulatory therapy designed to expand specific cancer-fighting T cells and natural killer (NK) cells directly in the tumor micro-environment and increase exp
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amazon (AMZN) October weekly call option implied volatility at 109 into Q3
- SolarCity (SCTY) October weekly 20 calls active into Tesla (TSLA) reporting Q3 results
- \Alphabet (GOOGL) October weekly call option implied volatility at 88 into Q3
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!